Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
for Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Drug: Botensilimab
Sites in Tyler, Dallas +4 more locations
Sponsor: Stingray Therapeutics
Sex: All·Age: 18+
Code: NCT06589440·Phase 2·Recruiting·Listed Sep 2024